Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of an immunomodulatory composition in the treatment of malignant effusion

A technology of immune regulation and composition, which is applied in the direction of drug combination, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., and can solve problems such as low efficiency, inability to cure the cause, and high requirements

Active Publication Date: 2022-03-04
GUANGZHOU BIOSYNGEN CO LTD
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current treatments are medically demanding, inefficient, and often fail to cure the cause

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of an immunomodulatory composition in the treatment of malignant effusion
  • Use of an immunomodulatory composition in the treatment of malignant effusion
  • Use of an immunomodulatory composition in the treatment of malignant effusion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] Embodiment 1 contains the preparation of polyIC composition (BSG) (following stabilizer is an example with kanamycin sulfate)

[0087] PI and PC are mixed according to the ratio between 0.5-1.5, add 200-2000IU kanamycin sulfate and 0.02-10mMCaCl 2 The solution was fixed to a certain volume with PBS, reacted for 30-60 minutes at a temperature not exceeding 60 degrees Celsius, filtered and subpackaged, and the filling volume was about 2ml / cartridge. Wherein the specific preparation examples are as follows.

[0088]

[0089]

Embodiment 2

[0090] Example 2 Saizheng (BSG) inhibits and treats ascites in H22 ascites tumor mice

[0091] Experimental background and purpose: Malignant ascites is a fluid in the peritoneal cavity caused by the transfer of digestive system tumors or ovarian cancer through blood vessels and lymphatic vessels, tumor tissue ulceration of the serosa layer, or radical surgery, often due to the shedding of cancer cells and implantation metastasis in the peritoneal cavity. Abnormal accumulation. This experiment was to investigate the inhibitory and therapeutic effects of BSG on ascites in H22 ascites tumor mice.

[0092] Experimental materials: mouse liver cancer cell line H22, female mice, 6-8 weeks old, 18-22g. Saizheng (BSG, containing PIC 2mg / ml, the same below). The control drug cisplatin (DDP), sterile N.S (ie normal saline).

[0093] experimental method:

[0094] 1. Establishment of the H22 ascites tumor model: Take out the frozen ascites cells, thaw them, add them to the medium for ...

Embodiment 3

[0117] Embodiment 3 The inhibitory and therapeutic effect of the composition Saizheng (BSG) of the present invention on mouse malignant pleural effusion

[0118] Experimental background and purpose: Malignant pleural effusion usually refers to the pleural effusion caused by the metastasis of malignant tumor in the pleura or other parts to the pleura, accounting for about 50% of all clinical pleural effusions. This experiment explores the inhibitory and therapeutic effects of the composition of the present invention (BSG) on the generation of malignant pleural effusion in mice.

[0119] Experimental materials: mouse liver cancer cell line H22 (purchased from CCTCC), BALB / c mice, SPF grade, female, 6-8 weeks old, 18-22g, purchased from Beijing Weitong Lihua. Saizheng (BSG, 2mg / ml). The control drug Adorson (cyclophosphamide for injection), CTX, lot number 6D111A, 0.2g, Baxter Oncology GmbH. Sodium chloride injection, manufacturer Zhejiang Tianrui Pharmaceutical Co., Ltd., batc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of an immunoregulatory composition in treating malignant effusion, wherein the composition has the function of immune regulation. It specifically relates to the use of the composition in the preparation of medicines for alleviating and treating malignant effusion, wherein the composition contains polyriboinosine-polyribocytidylic acid (PIC). The composition may further comprise at least one stabilizer and calcium ions, anticancer agents or other pharmaceutically acceptable carriers.

Description

technical field [0001] The present invention relates to the use of an immunomodulatory composition in preventing and / or treating malignant effusion. Background technique [0002] Malignant pleural effusion (MPE) generally refers to the presence of malignant cells in pleural fluid or pleural tissue. It is common in patients with advanced malignancies (1). Common symptoms associated with MPE are dyspnea, cough, fatigue, wasting, and pleuritic pain. [0003] A classic view of the formation of MPE is the stagnation of pleural effusion due to the development of tumor in the pleural cavity and the obstruction of lymphatic vessels. These pleural-based tumor metastases block pleural drainage while increasing pleural fluid production by increasing plasma extravasation into the pleural cavity. MPEs are now believed to arise from complex biological interactions between host blood vessels and tumor cells that involve regulators of the host immune system (2). [0004] There are about...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/787A61K31/7036A61K33/14A61K45/06A61P35/00A61P37/02
CPCA61K31/7036A61K31/787A61K33/14A61K45/06A61K2300/00A61K31/7088A61K33/06A61P37/02A61P35/04A61P35/00A61K31/713A61K39/0011A61K39/12A61K47/36C07H21/02
Inventor 叶升
Owner GUANGZHOU BIOSYNGEN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com